{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cutaneous&page=62",
    "query": {
      "condition": "Cutaneous",
      "page": 62
    },
    "page_size": 10
  },
  "pagination": {
    "page": 62,
    "page_size": 10,
    "total_count": 1581,
    "total_pages": 159,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cutaneous&page=63&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cutaneous&page=61&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T02:11:13.708Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05138458",
      "title": "A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, T-Cell, Peripheral",
        "Lymphoma, T-Cell, Cutaneous",
        "Mycosis Fungoides",
        "Adoptive Cellular Immunotherapy",
        "Cell Therapy"
      ],
      "interventions": [
        {
          "name": "MT-101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MT-101 + Conditioning (Lymphodepleting) Chemotherapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Myeloid Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2021-12-15",
      "completion_date": "2025-10",
      "has_results": false,
      "last_update_posted_date": "2023-11-13",
      "last_synced_at": "2026-11-15T02:11:13.708Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Denver, Colorado • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05138458"
    },
    {
      "nct_id": "NCT02283762",
      "title": "Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Scleroderma, Systemic"
      ],
      "interventions": [
        {
          "name": "Riociguat (Adempas, BAY63-2521)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2015-01-15",
      "completion_date": "2019-03-28",
      "has_results": true,
      "last_update_posted_date": "2020-02-05",
      "last_synced_at": "2026-11-15T02:11:13.708Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02283762"
    },
    {
      "nct_id": "NCT05202782",
      "title": "Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation",
        "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Large B-Cell Lymphoma With IRF4 Rearrangement",
        "Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type",
        "Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Recurrent Intravascular Large B-Cell Lymphoma",
        "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma",
        "Recurrent Transformed B-Cell Non-Hodgkin Lymphoma",
        "Refractory Aggressive B-Cell Non-Hodgkin Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Refractory Intravascular Large B-Cell Lymphoma",
        "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma",
        "Refractory Transformed B-Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Chimeric Antigen Receptor T-Cell Therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Zanubrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2022-03-21",
      "completion_date": "2029-10-09",
      "has_results": false,
      "last_update_posted_date": "2024-10-16",
      "last_synced_at": "2026-11-15T02:11:13.708Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05202782"
    },
    {
      "nct_id": "NCT01641796",
      "title": "Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Leishmaniasis, Cutaneous"
      ],
      "interventions": [
        {
          "name": "Paromomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-05-15",
      "last_synced_at": "2026-11-15T02:11:13.708Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Multiple Locations, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Multiple Locations",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01641796"
    },
    {
      "nct_id": "NCT00103246",
      "title": "Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Non-melanomatous Skin Cancer",
        "Precancerous Condition"
      ],
      "interventions": [
        {
          "name": "silicon phthalocyanine 4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 43,
      "start_date": "2004-09",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2019-01-22",
      "last_synced_at": "2026-11-15T02:11:13.708Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00103246"
    },
    {
      "nct_id": "NCT04830124",
      "title": "Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cutaneous Melanoma",
        "Mucosal Melanoma"
      ],
      "interventions": [
        {
          "name": "Nemvaleukin Alfa Subcutaneous",
          "type": "DRUG"
        },
        {
          "name": "Nemvaleukin Alfa Intravenous",
          "type": "DRUG"
        },
        {
          "name": "Nemvaleukin Alfa Intravenous Less Frequent Dosing",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mural Oncology, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 173,
      "start_date": "2021-09-27",
      "completion_date": "2025-05-08",
      "has_results": false,
      "last_update_posted_date": "2025-06-10",
      "last_synced_at": "2026-11-15T02:11:13.708Z",
      "location_count": 10,
      "location_summary": "La Jolla, California • Los Angeles, California • Jacksonville, Florida + 5 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04830124"
    },
    {
      "nct_id": "NCT04138485",
      "title": "Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Cutaneous Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "IgPro10",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-12-20",
      "completion_date": "2020-09-16",
      "has_results": false,
      "last_update_posted_date": "2020-11-17",
      "last_synced_at": "2026-11-15T02:11:13.708Z",
      "location_count": 20,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04138485"
    },
    {
      "nct_id": "NCT01451125",
      "title": "A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Androgenetic Alopecia",
        "Male Pattern Baldness",
        "Female Pattern Baldness"
      ],
      "interventions": [
        {
          "name": "Autologous cultured dermal and epidermal cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Aderans Research Institute",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 43,
      "start_date": "2010-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-07-11",
      "last_synced_at": "2026-11-15T02:11:13.708Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Pinellas Park, Florida + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Pinellas Park",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01451125"
    },
    {
      "nct_id": "NCT02152215",
      "title": "Ridge Preservation Comparing a Polylactic Acid Membrane vs. an Acellular Dermal Matrix Membrane",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Ridge Preservation"
      ],
      "interventions": [
        {
          "name": "Acellular dermal matrix membrane",
          "type": "PROCEDURE"
        },
        {
          "name": "Polylactic acid membrane",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2014-07",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2016-12-08",
      "last_synced_at": "2026-11-15T02:11:13.708Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02152215"
    },
    {
      "nct_id": "NCT03043768",
      "title": "Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "GWT-TUD GmbH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "35 Years to 80 Years"
      },
      "enrollment_count": 50,
      "start_date": "2016-06-01",
      "completion_date": "2018-01-28",
      "has_results": false,
      "last_update_posted_date": "2022-07-22",
      "last_synced_at": "2026-11-15T02:11:13.708Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03043768"
    }
  ]
}